Algorae Pharmaceuticals Ltd - Company Profile
Powered by 
All the data and insights you need on Algorae Pharmaceuticals Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Algorae Pharmaceuticals Ltd Strategy Report
- Understand Algorae Pharmaceuticals Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Algorae Pharmaceuticals Ltd (Algorae Pharmaceuticals), previously Living Cell Technologies Ltd (LCT) is a biotechnology company that discovery, development and commercialization of novel therapeutics for the treatment of debilitating conditions such as Parkinson’s disease, cardiovascular disease, and Alzheimer’s disease. It focuses on discovering regenerative treatments which restore function using naturally occurring cells. Its pipeline products include, NTCELL an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells. It is in Phase IIb clinical trials for the treatment of Parkinson's disease. It is also investigating AI-116 for the treatment of dementia and AI-168 for cardiovascular diseases. The company has partnerships collaborations with universities and pharmaceutical companies for development of its product candidates. Algorae Pharmaceuticals is headquartered in Melbourne, Victoria, Australia.
Headquarters
Australia
Address
L 7 330 Collins St, Melbourne, Victoria, 3000
Website
www.algoraepharma.com
Telephone
61 2 89990970
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
1AI (ASX)
Revenue (2022)
$29,100
1132.3%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-7.7%
(2022 vs 2021)
Market Cap*
$11.0M
Net Profit Margin (2022)
XYZ
91.3%
(2022 vs 2021)
* As of and is in US$
Algorae Pharmaceuticals Ltd premium industry data and analytics
Products and Services
| Products |
|---|
| NTCELL |
| AI-116 |
| AI-168 |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In December, the company entered into an agreement with HL Pharma to import and warehouse company-owned cannabinoids and other compounds for distribution to its research partners as required. |
| 2023 | Contracts/Agreements | In October, the company entered into a collaboration with the University of New South Wales (UNSW) to establish an artificial intelligence platform for drug discovery and enhanced development outcomes. |
| 2023 | Corporate Changes/Expansions | In July, the company announced its plans to change its name to Algorae Pharmaceuticals Limited. |
Competitor Comparison
| Key Parameters | Algorae Pharmaceuticals Ltd | Mesoblast Ltd | Exopharm Ltd | Accelagen Pty Ltd | Biosensis Pty Ltd |
|---|---|---|---|---|---|
| Headquarters | Australia | Australia | Australia | Australia | Australia |
| City | Melbourne | Melbourne | Melbourne | Hawthorn East | Thebarton |
| State/Province | Victoria | Victoria | Victoria | Victoria | South Australia |
| No. of Employees | - | 83 | - | - | - |
| Entity Type | Public | Public | Public | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| David Hainsworth | Chairman | Executive Board | 2022 | - |
| Daya Uka | Chief Financial Officer | Senior Management | 2016 | - |
| Belinda Di Bartolo | Chief Operating Officer | Senior Management | 2021 | - |
| James A Mckenna | Chief Scientific Officer | Senior Management | 2023 | - |
| Leah Pieris | Secretary | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer